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We found a 13% macrolide resistance in 3,866
Streptococcus pyogenes isolated from tonsillopharyngitis
patients; 59% macrolide-resistant isolates were distributed
in 5 clones, suggesting the importance of both resistance
gene transfer and clonal dissemination in the spread of
these organisms. We also report one of the largest collec-
tions of telithromycin-resistant isolates.
S
treptococcus pyogenes causes several million cases of
upper respiratory tract infection each year. The problem
of these infections is growing as resistance increases
among S. pyogenes to the macrolide group of antimicrobial
drugs commonly used to treat such infections (1–4). S.
pyogenes acquires resistance by 2 main mechanisms. The
first is active drug efflux mediated by an ATP-binding cas-
sette transporter wherein mef(A) encodes the transmem-
brane domains and msr(D) encodes the ATP-binding
domains (5). This pattern of resistance is demonstrated by
an M phenotype. In the second mechanism, gene products
of erm(B) or erm(A) methylate the macrolide-binding site
on 23S rRNA and stall bacterial protein synthesis. This
pattern of resistance is demonstrated by either a constitu-
tive (cMLS) or an inducible (iMLS) phenotype. A third,
rare, mechanism is modification of the drug binding site on
rRNA by mutation that is expressed as an M or a cMLS
phenotype. The newest generation of macrolides, the
ketolides, are also active against macrolide-resistant
strains; however, few S. pyogenes strains of the cMLS phe-
notype have been found to be ketolide resistant (6).
In Belgium, the first ketolide to be used clinically,
telithromycin, was approved in October 2002 to treat com-
munity-acquired respiratory infections in patients >12
years of age. We investigated the temporal trends in
resistance and clonality among macrolide (including
telithromycin)-resistant  S. pyogenes recovered from
patients with tonsillopharyngitis during surveillance stud-
ies conducted in Belgium.
The Study
During 1999–2003, a total of 4,031 nonduplicate, puta-
tive S. pyogenes isolates were collected from 10 Belgian
provinces at the reference center with the date of isolation,
specimen source, and patient’s age and residential address.
By using a battery of tests, for example, β-hemolysis on
blood agar, Gram stain, catalase production, pyrrolidonyl
arylamidase, presence of Group A antigen, and bacitracin
susceptibility, 3,866 isolates were confirmed to be S. pyo-
genes. The age of the patient was known in 3,654 cases.
Population statistics are detailed in the first half of Table 1.
By using erythromycin (78 µg) and clindamycin (25
µg) double-disk diffusion (Neo-Sensitab discs; Rosco,
Taastrup, Denmark), all 3,866 S. pyogenes isolates were
further screened for a phenotypic expression of macrolide
resistance, which was identified in 506 (13%) isolates. The
proportion of macrolide-resistant isolates among the total
S. pyogenes isolated from each of the 10 Belgian provinces
fluctuated from 0% to 40% over the 5 years studied. The 3
known phenotypes, cMLS, iMLS, and M, were identified
in 209 (41%), 18 (4%), and 279 (55%) isolates, respective-
ly. Changes in prevalence of the 3 phenotypes among
macrolide-resistant S. pyogenes over 5 years are presented
in the second half of Table 1. 
MICs of erythromycin, clindamycin, tetracycline
(Sigma-Aldrich, St. Louis, MO, USA), clarithromycin
(Abbott, Louvain-la-Neuve, Belgium), azithromycin
(Pfizer, Groton, CT, USA), and telithromycin (Aventis,
Romainville, France) were further determined by agar
dilution (7). Susceptible and resistance breakpoints for
telithromycin were <1 µg/mL and >4 µg/mL, respectively.
Briefly, a 104 CFU/spot inoculum was incubated at 37°C
for 18–24 h in ambient air. The MIC profiles of the 3
macrolide-resistant phenotypes to various antimicrobial
drugs are presented in the online Appendix Table 1 (avail-
able at http://www.cdc.gov/ncidod/eid/vol11no06/04-
1247_ app1.htm). The yearly prevalence (1999–2003) of
telithromycin resistance (MIC >4  µg/mL) among
macrolide-resistant S. pyogenes was 2%, 7%, 11%, 13%,
and 10%, respectively. Thus, the total telithromycin-resist-
ant isolates (N = 50) identified here constitute the largest
collection reported. Of the 50 telithromycin-resistant S.
pyogenes, 49 belonged to the cMLS and 1 to the iMLS
phenotype. These isolates exhibited erythromycin MICs of
128–>512  µg/mL. Thirty (60%) telithromycin-resistant
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therapy, October 30–November 2, 2004, Washington DC, USA.S. pyogenes were isolated from children, of which 28
(56%) were <12 years of age.
We further investigated clonality in all macrolide-
resistant isolates and in a random selection of 331
macrolide-susceptible isolates by pulsed-field gel elec-
trophoresis (PFGE) and emm typing on reverse line blot-
ting as described previously (1). PFGE was performed by
using  SmaI; however, for most mef(A)-positive isolates
that proved refractory to SmaI restriction, SfiI restriction
was utilized. PFGE patterns were analyzed by using
GelCompar software 4.0 (Applied Maths, Kortrijk,
Belgium). The 506 macrolide-resistant S. pyogenes were
typed into 17 emm types and 76 PFGE types, of which 53
(70%) types were distributed among M phenotype isolates
(Appendix Table 2 available at http://www.cdc.gov/nci-
dod/eid/vol11no06/04-1247_app2.htm). Ratios of PFGE
types to number of S. pyogenes isolates were 0.18 and 0.09
for the M and cMLS phenotypes, respectively. Table 2
shows the temporal evolution over 5 years of the 5 major
cMLS and M phenotype clones. Clones 1, 4, and 23 con-
stituted 99%, 98%, and 100% of all the macrolide-resistant
emm22, emm28, and emm11, respectively, isolated during
the course of this study, while clones 1,001 and 1,002 con-
stituted 97% and 39% of the emm1 and emm4 macrolide-
resistant  S. pyogenes serotypes, respectively. Serotypes
emm1, emm4, emm11, emm22 and emm28 formed 70% of
the total macrolide-resistant S. pyogenes. Among the 331
macrolide-susceptible  S. pyogenes analyzed, the preva-
lence of clones 1, 4, 23, 1,001, and 1,002 was 5% (n = 18),
1% (n = 3), 0.3% (n = 1), 2% (n = 5), and 0.3% (n = 1),
respectively (data not shown). Telithromycin resistance
was distributed among 7 cMLS serotypes (emm22,
emm28, emm11, emm12, emm77, emm6, and, emm2).
We next studied the genotype for the 3 macrolide-resist-
ant phenotypes. Polymerase chain reaction was performed
for erm(A), erm(B), and mef(A) (1,9,10). Isolates negative
for all 3 genes were screened for ribosomal mutations in
L4, L22, and portions of 23S RNA genes by using pub-
lished primers (11). Amplimers were analyzed by direct
double-strand sequencing (3730 DNA Analyzer, Applied
Biosystems, Foster City, CA, USA) with the BigDye
Terminator Version 3.1 Kit (Applied Biosystems).
Nucleotide sequence alignment was done with SeqMan
(DNASTAR Inc., Madison, WI, USA). Phenotypic and
genotypic profiles of the macrolide-resistant S. pyogenes
were generally consistent; however, 3% of the resistant iso-
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199 carried erm(B), 9 carried erm(B)+mef(A), and 1 carried
erm(B)+erm(A). Of the 279 M phenotype isolates, 273
carried  mef(A), 1 carried erm(B)+mef(A), and 4 carried
mef(A)+erm(A). The 1 isolate that was negative for all 3
genes carried a single A2059G (Escherichia coli number-
ing system) mutation in the 23S rRNA gene. The A2059G
mutation, although quite frequent in S. pneumoniae, has
been rarely observed in S. pyogenes. Finally, of the 18
iMLS isolates, 5 carried erm(B) and 13 carried erm(A).
Ten percent of the macrolide-resistant strains harboring
erm(B) alone or with mef(A) were also telithromycin-
resistant, and telithromycin has additional binding sites on
23S rRNA. Therefore, we hypothesized that either muta-
tions in the erm gene promoter region have upregulated
methylase expression or that mutations in the coding
region have changed the methylase specificity to include
the additional binding sites of telithromycin. Alternatively,
mutations at the additional binding sites on the 23S rRNA
genes might also disable the binding arm; however, a
recent study described only a low level of telithromycin
resistance in the presence of these mutations (12).
Utilizing 3 pairs of overlapping primers (primer sequences
available on request), DNASTAR software, and sequence
data of Tn1545 (National Center for Biotechnology
Information, Rockville, MD, USA, accession no.
X52632), the entire erm(B) gene, including the promoter
and control peptides, were sequenced from 10
telithromycin-resistant isolates. In addition, L4, L22, and
portions of 23S rRNAgenes were also amplified as above.
Analysis of the sequencing data showed a single H118R
(A677G) substitution in the erm(B) coding region of all 10
telithromycin-resistant isolates. While our study was ongo-
ing, the H118R substitution in erm(B) was also confirmed
independently for 2 telithromycin-resistant isolates (6).
Conclusions
We demonstrated in this study that overall macrolide
resistance in Belgium is driven by an epidemic spread of a
few major clones as well as by resistance gene transfer
among genetically diverse S. pyogenes. On average, we
demonstrated a 2-fold (13%) increase in macrolide resist-
ance in Belgium from 1999 to 2003, compared to that
observed from 1995 to 1997 (6.5%) (1). Although, a gen-
eral increase in macrolide-resistance in Europe has been
observed during the last few years, resistance levels tend to
differ considerably between countries. For instance, while
resistance rates in Germany (6) and Poland (4) were simi-
lar to those observed in Belgium, considerably higher
resistance levels were observed in Spain and Portugal (2),
as well as in Italy (3). Provincial variations in macrolide-
resistance observed in Belgium have also been reported in
other countries (3); however, the precise causes underlying
such variations within or between countries are not fully
understood. Macrolide consumption might be one factor
that explains the regional variations in macrolide-resistant
S. pyogenes in Spain and Finland (13,14), especially when
consumption surpasses a critical threshold (15). However,
in France, one of the highest macrolide consumption with-
in Europe is not paralleled by an equally high resistance in
S. pyogenes (16,17). The identification of telithromycin-
resistant S. pyogenes in our study, many of which were
already present in the community before the introduction
of telithromycin in Belgium, also suggest that antimicro-
bial drug use and development of resistance might be dis-
sociated to some extent. Clearly, other factors like natural
fluctuations in prevalence of clones (18), patient compli-
ance with antimicrobial drug regimens, fitness costs of
drug resistance, or even tetracycline consumption (tetracy-
cline and macrolide-resistance genes cosegregate) (19)
might be important determinants for the development and
spread of macrolide-resistant S. pyogenes. Thus, any direct
link between macrolide use and resistance in S. pyogenes
should be interpreted cautiously.
Acknowledgments
We thank the following centers in Belgium for their partici-
pation in this study: AML BVBA, Antwerp; Laboratoire de
Biologie Clinique et Hormonale - S.P.R.L., Couillet; Centraal
Laboratorium, Hasselt; Medisch Centrum Huisarten, Leuven;
Centre Hospitalier de L’Ardenne Laboratoire de Biologie
Clinique et de Ria, Libramont; Laboratoire Marchand, Liège.
This study was partly funded by the Belgian Antibiotic
Policy Co-ordination Committee (BAPCOC).
Ms. Malhotra-Kumar holds a double master’s degree in
medical microbiology and molecular biology and is a final-year
PhD student at the University of Antwerp. Her main research
focuses on the epidemiology and molecular genetics of antimi-
crobial resistance in oral streptococci.
References
1.  Descheemaeker P, Chapelle S, Lammens C, Hauchecorne M,
Wijdooghe M, Vandamme P, et al. Macrolide resistance and erythro-
mycin resistance determinants among Belgian Streptococcus pyo-
genes and  Streptococcus pneumoniae isolates. J Antimicrob
Chemother. 2000;45:167–73.
2. Canton R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance
amongst isolates of Streptococcus pyogenes and  Staphylococcus
aureus in the PROTEKT antimicrobial surveillance programme dur-
ing 1999–2000. J Antimicrob Chemother. 2002;50(Suppl S1):9–24.
3. Cornaglia G, Ligozzi M, Mazzariol A, Masala L, Lo CG, Orefici G, et
al. Resistance of Streptococcus pyogenes to erythromycin and related
antibiotics in Italy. The Italian Surveillance Group for Antimicrobial
Resistance. Clin Infect Dis. 1998;27(Suppl 1):S87–S92.
4. Szczypa K, Sadowy E, Izdebski R, Hryniewicz W. Arapid increase in
macrolide resistance in Streptococcus pyogenes isolated in Poland
during 1996–2002. J Antimicrob Chemother. 2004;54:828–31.
Macrolide- and Telithromycin-resistant Streptococcus pyogenes
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005 9415. Iannelli F, Santagati M, Docquier JD, Cassone M, Oggioni MR,
Rossolini G, et al. Type M resistance to macrolides in streptococci is
not due to the mef(A) gene, but to mat(A) encoding an ATP-depend-
ent efflux pump [Abstract C1-1188]. Presented at the 44th
Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC); Washington; 2004 Oct 30–Nov 2.
6. Reinert RR, Lutticken R, Sutcliffe JA, Tait-Kamradt A, Cil MY,
Schorn HM, et al. Clonal relatedness of erythromycin-resistant
Streptococcus pyogenes isolates in Germany. Antimicrob Agents
Chemother. 2004;48:1369–73.
7.  NCCLS. National Committee for Clinical laboratory Standards.
Performance standards for antimicrobial susceptibility testing.
Twelfth informational supplement, M100-S12. Wayne (PA); The
Committee; 2002.
8. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE,
Persing DH, et al. Interpreting chromosomal DNArestriction patterns
produced by pulsed-field gel electrophoresis: criteria for bacterial
strain typing. J Clin Microbiol. 1995;33:2233–9.
9.  Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of
erythromycin-resistant determinants by PCR. Antimicrob Agents
Chemother. 1996;40:2562–6.
10. Malhotra-Kumar S, Wang S, Lammens C, Chapelle S, Goossens H.
Bacitracin-resistant clone of Streptococcus pyogenes isolated from
pharyngitis patients in Belgium. J Clin Microbiol. 2003;41:5282–4.
11. Malbruny B, Nagai K, Coquemont M, Bozdogan B, Andrasevic AT,
Hupkova H, et al. Resistance to macrolides in clinical isolates of
Streptococcus pyogenes due to ribosomal mutations. J Antimicrob
Chemother. 2002;49:935–9.
12. Novotny GW, Jakobsen L, Andersen NM, Poehlsgaard J, Douthwaite
S. Ketolide antimicrobial activity persists after disruption of interac-
tions with domain II of 23S rRNA. Antimicrob Agents Chemother.
2004;48:3677–83.
13. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE.
Pharmacoepidemiological analysis of provincial differences between
consumption of macrolides and rates of erythromycin resistance
among Streptococcus pyogenes isolates in Spain. J Clin Microbiol.
2002;40:2959–63.
14.  Bergman M, Huikko S, Pihlajamaki M, Laippala P, Palva E,
Huovinen P, et al. Effect of macrolide consumption on erythromycin
resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin
Infect Dis. 2004;38:1251–6.
15. Granizo JJ, Aguilar L, Casal J, Dal Re R, Baquero F. Streptococcus
pyogenes resistance to erythromycin in relation to macrolide con-
sumption in Spain (1986–1997). J Antimicrob Chemother.
2000;46:959–64.
16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient
antibiotic use in Europe and association with resistance. Lancet.
2005;365:579–87.
17. Weber P, Filipecki J, Bingen E, Fitoussi F, Goldfarb G, Chauvin JP, et
al. Genetic and phenotypic characterization of macrolide resistance in
group A streptococci isolated from adults with pharyngo-tonsillitis in
France. J Antimicrob Chemother. 2001;48:291–4.
18. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group
A streptococcal serotypes associated with pharyngitis. Lancet.
2001;358:1334–7.
19. Nielsen HU, Hammerum AM, Ekelund K, Bang D, Pallesen LV,
Frimodt-Moller N. Tetracycline and macrolide co-resistance in
Streptococcus pyogenes: co-selection as a reason for increase in
macrolide-resistant  S. pyogenes? Microb Drug Resist.
2004;10:231–8.
Address for correspondence: Surbhi Malhotra-Kumar, Department of
Medical Microbiology, Campus Drie Eiken, University of Antwerp, S3,
Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium; fax: 32-3-820-
26-63; email: surbhi.malhotra@ua.ac.be
DISPATCHES
942 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005
The print journal is available at no charge to public health professionals
YES, I would like to receive Emerging Infectious Diseases.
Please print your name and business
address in the box and return by fax to
404-371-5449 or mail to
EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333
Moving? Please give us your new address (in the box) and print the number of your old
mailing label here_________________________________________
	



